{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:16:20Z","timestamp":1793823380130,"version":"4.6.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T00:00:00Z","timestamp":1544745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Finnish Awarded Special State Subsidy EVO","award":["TYH 2014203"],"award-info":[{"award-number":["TYH 2014203"]}]},{"name":"Finnish Cancer Foundation","award":["4703666"],"award-info":[{"award-number":["4703666"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.humpath.2018.11.020","type":"journal-article","created":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T02:50:54Z","timestamp":1544237454000},"page":"66-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas"],"prefix":"10.1016","volume":"86","author":[{"given":"Helena","family":"Leijon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"Remes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaana","family":"Hagstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Louhimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"M\u00e4enp\u00e4\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Schalin-J\u00e4ntti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku","family":"Miettinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caj","family":"Haglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Arola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2018.11.020_bb0005","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.5858\/2008-132-1272-PAEPU","article-title":"Pheochromocytoma and extra-adrenal paraganglioma: updates","volume":"132","author":"Tischler","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2018.11.020_bb0010","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjsurg.2010.04.012","article-title":"Malignant pheochromocytoma: a review","volume":"201","author":"Harari","year":"2011","journal-title":"Am J Surg"},{"key":"10.1016\/j.humpath.2018.11.020_bb0015","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/jso.24063","article-title":"Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: a single institution experience","volume":"112","author":"Choi","year":"2015","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.humpath.2018.11.020_bb0020","series-title":"WHO Classification of Tumours of Endocrine Organs","first-page":"180","article-title":"Pheochromocytoma, extra-adrenal paragangliomas","author":"Tischler","year":"2017"},{"key":"10.1016\/j.humpath.2018.11.020_bb0025","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2002-0007","article-title":"Peptide receptors as molecular targets for cancer diagnosis and therapy","volume":"24","author":"Reubi","year":"2003","journal-title":"Endocr Rev"},{"key":"10.1016\/j.humpath.2018.11.020_bb0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.beem.2016.01.001","article-title":"Specific biology of neuroendocrine tumors: peptide receptors as molecular targets","volume":"30","author":"Korner","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.humpath.2018.11.020_bb0035","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.humpath.2014.11.012","article-title":"Increased SSTR2A and SSTR3 expression in succinate dehydrogenase\u2013deficient pheochromocytomas and paragangliomas","volume":"46","author":"Elston","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2018.11.020_bb0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000371804","article-title":"Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors?","volume":"101","author":"Korner","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.humpath.2018.11.020_bb0045","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s40265-015-0397-7","article-title":"The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors","volume":"75","author":"Cives","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.humpath.2018.11.020_bb0050","article-title":"Somatostatin receptor based imaging and radionuclide therapy","volume":"2015","author":"Xu","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.humpath.2018.11.020_bb0055","doi-asserted-by":"crossref","first-page":"E1730","DOI":"10.1210\/jc.2013-2145","article-title":"Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide","volume":"98","author":"Casar-Borota","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.humpath.2018.11.020_bb0060","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2016.01.022","article-title":"Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era","volume":"100","author":"Pillai","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.humpath.2018.11.020_bb0065","doi-asserted-by":"crossref","first-page":"T91","DOI":"10.1530\/ERC-15-0268","article-title":"15 Years of paraganglioma: Clinical manifestations of paraganglioma syndromes types 1-5","volume":"22","author":"Benn","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.humpath.2018.11.020_bb0070","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1053\/j.semdp.2013.06.006","article-title":"Paragangliomas: update on differential diagnostic considerations, composite tumors, and recent genetic developments","volume":"30","author":"Papathomas","year":"2013","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.humpath.2018.11.020_bb0075","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/modpathol.2015.41","article-title":"SDHB\/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a multinational study of the European Network for the Study of Adrenal Tumors (ENS@T)","volume":"28","author":"Papathomas","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2018.11.020_bb0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/PAI.0b013e31828bfdd3","article-title":"Mapping of succinate dehydrogenase losses in 2258 epithelial neoplasms","volume":"22","author":"Miettinen","year":"2014","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.humpath.2018.11.020_bb0085","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/PAS.0b013e31823d07f3","article-title":"Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting","volume":"36","author":"Korner","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2018.11.020_bb0090","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/modpathol.3800954","article-title":"Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy","volume":"20","author":"Volante","year":"2007","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2018.11.020_bb0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000074662","article-title":"Somatostatin receptors in pheochromocytoma","volume":"31","author":"de Herder","year":"2004","journal-title":"Front Horm Res"},{"key":"10.1016\/j.humpath.2018.11.020_bb0100","doi-asserted-by":"crossref","first-page":"89958","DOI":"10.18632\/oncotarget.21194","article-title":"D'Haese CXCR4 chemokine and endothelin a receptor expression in a large set of paragangliomas","volume":"8","author":"Kaemmerer","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2018.11.020_bb0105","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1210\/jc.2003-030262","article-title":"Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy","volume":"88","author":"Mundschenk","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.humpath.2018.11.020_bb0110","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1365-2265.2007.03124.x","article-title":"Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours","volume":"68","author":"Unger","year":"2008","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.humpath.2018.11.020_bb0115","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/MPA.0000000000000700","article-title":"Association between somatostatin receptor expression and clinical outcomes in neuroendocrine tumors","volume":"45","author":"Qian","year":"2016","journal-title":"Pancreas"},{"key":"10.1016\/j.humpath.2018.11.020_bb0120","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3892\/ol.2017.5591","article-title":"Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors","volume":"13","author":"Wang","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.humpath.2018.11.020_bb0125","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.humpath.2018.11.020_bb0130","doi-asserted-by":"crossref","first-page":"27566","DOI":"10.18632\/oncotarget.4491","article-title":"Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy","volume":"6","author":"Kaemmerer","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2018.11.020_bb0135","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MED.0000000000000330","article-title":"Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials","volume":"24","author":"Roman-Gonzalez","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"Suppl. 2","key":"10.1016\/j.humpath.2018.11.020_bb0140","doi-asserted-by":"crossref","first-page":"42S","DOI":"10.2967\/jnumed.110.085753","article-title":"Radiopeptide imaging and therapy in Europe","volume":"52","author":"Ambrosini","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.humpath.2018.11.020_bb0145","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1007\/s00259-003-1255-5","article-title":"DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals","volume":"30","author":"Wild","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.humpath.2018.11.020_bb0150","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1530\/ERC-11-0382","article-title":"Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors","volume":"19","author":"Chan","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.humpath.2018.11.020_bb0155","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/5584_2016_76","article-title":"Phaeochromocytoma and paraganglioma","volume":"956","author":"Gunawardane","year":"2017","journal-title":"Adv Exp Med Biol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681771830474X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681771830474X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T19:25:35Z","timestamp":1694460335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004681771830474X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":31,"alternative-id":["S004681771830474X"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2018.11.020","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2018.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}